gabexate has been researched along with Pancreatic Diseases in 6 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Pancreatic Diseases: Pathological processes of the PANCREAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 9.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "A continuous 13-h infusion of gabexate starting 30-90 min before endoscopic cholangiopancreatography (ERCP) can reduce postprocedural pancreatitis, the onset of which is generally observed within the first 6 h after ERCP." | 9.10 | Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. ( Cavallini, G; Costamagna, G; Curioni, S; Dragonetti, C; Frulloni, L; Innocenti, P; Macarri, G; Mariani, A; Masci, E; Testoni, PA; Tittobello, A; Uomo, G; Zambelli, S, 2003) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 7.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 5.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "A continuous 13-h infusion of gabexate starting 30-90 min before endoscopic cholangiopancreatography (ERCP) can reduce postprocedural pancreatitis, the onset of which is generally observed within the first 6 h after ERCP." | 5.10 | Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. ( Cavallini, G; Costamagna, G; Curioni, S; Dragonetti, C; Frulloni, L; Innocenti, P; Macarri, G; Mariani, A; Masci, E; Testoni, PA; Tittobello, A; Uomo, G; Zambelli, S, 2003) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 3.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sai, JK | 1 |
| Suyama, M | 1 |
| Kubokawa, Y | 1 |
| Matsumura, Y | 1 |
| Inami, K | 1 |
| Watanabe, S | 1 |
| Manfredi, R | 1 |
| Calza, L | 1 |
| Chiodo, F | 1 |
| Masci, E | 1 |
| Cavallini, G | 1 |
| Mariani, A | 1 |
| Frulloni, L | 1 |
| Testoni, PA | 1 |
| Curioni, S | 1 |
| Tittobello, A | 1 |
| Uomo, G | 1 |
| Costamagna, G | 1 |
| Zambelli, S | 1 |
| Macarri, G | 1 |
| Innocenti, P | 1 |
| Dragonetti, C | 1 |
| Emori, Y | 1 |
| Mizushima, T | 1 |
| Matsumura, N | 1 |
| Ochi, K | 1 |
| Tanioka, H | 1 |
| Shirahige, A | 1 |
| Ichimura, M | 1 |
| Shinji, T | 1 |
| Koide, N | 1 |
| Tanimoto, M | 1 |
| Watanapa, P | 1 |
| Williamson, RC | 1 |
| Oishi, T | 1 |
| Nakagawa, M | 1 |
| Bamba, T | 1 |
| Hosoda, S | 1 |
1 review available for gabexate and Pancreatic Diseases
| Article | Year |
|---|---|
Experimental pancreatic hyperplasia and neoplasia: effects of dietary and surgical manipulation.
Topics: Animals; Cricetinae; Diet; Disease Models, Animal; Energy Intake; Esters; Flour; Gabexate; Glycine m | 1993 |
2 trials available for gabexate and Pancreatic Diseases
| Article | Year |
|---|---|
Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.
Topics: Abdominal Pain; Adult; Aged; Dyspepsia; Endosonography; Esters; Female; Gabexate; Guanidines; Humans | 2010 |
Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Biliary Tract Diseases; Cholangiopancreat | 2003 |
3 other studies available for gabexate and Pancreatic Diseases
| Article | Year |
|---|---|
Gabexate mesilate and/or octreotide in human immunodeficiency virus-associated pancreatic abnormalities.
Topics: Adult; Case-Control Studies; Drug Combinations; Female; Gabexate; HIV Infections; Humans; Male; Octr | 2002 |
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Ditiocarb; Drug Administration Schedule; Este | 2005 |
[Study on the trophic effect of camostate mesilate on ethionine-induced pancreatic injury rat].
Topics: Administration, Oral; Amylases; Animals; Cholecystokinin; Esters; Ethionine; Gabexate; Guanidines; I | 1989 |